Clinical trials: SAR
Allergic Rhinitis, Rhinitis, Allergic, Seasonal
A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis
This study is an 8 day, randomised, double blind, 2-way crossover trial of repeat doses of intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR).
- Trial name
- NCT00612118
- Testing
- GSK256066, azelastine hydrochloride
- Where
- Austria
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, SAR
(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC
Coronavirus disease (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents a major threat to human health.
- Trial name
- NCT04777981
- Testing
- CBDRA60 supplement
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Anewsha Therapeutics Inc.
Rhinitis, Allergic, Seasonal
A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)
This is an 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR).
- Trial name
- NCT00612820
- Testing
- GSK256066, fluticasone propionate
- Where
- Austria
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Allergic Conjunctivitis
Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)
To evaluate the efficacy of olopatadine 0.1% using the OHIO Chamber in patients with seasonal allergic conjunctivitis.
- Trial name
- NCT00818805
- Testing
- Olopatadine 0.1%, Tranilast 0.5%
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Alcon Research
SAR-CoV-2, Cellular Immune Response
Study of Immune Response in Subjects Vaccinated Against SARS-CoV-2 Infection
Twelve months after the first SARS-CoV-2 cases in Wuhan, the FDA approved the first COVID-19 vaccine (Pfizer-BioNTech). Early studies on healthcare workers showed that antibody levels, especially against the Spike protein…
- Conditions
- SAR-CoV-2, Cellular Immune Response, Antibody Response
- Trial name
- BioVAC-immunit (NCT07049497)
- Testing
- Evaluation of the T cell response in terms of IFN-γ measured by ELISpot
- Where
- Italy
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
CAD
Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System
Background: Researchers are testing version of a system known as a magnetic resonance imagining (MRI) scanner that uses strong magnetic fields, radio waves and the like to create images of the organs in the body.
- Trial name
- NCT03331380
- Testing
- MRI scan - obj 1, MRI scans - obj 2, MRI scans - obj 3
- Where
- United States
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hay Fever
Safety and Efficacy Study of rEV131 in Allergic Rhinitis
The purpose of this study is to see whether rEV131 when given as a nasal spray in a single dose to each nostril is safe and can reduce the signs and symptoms of allergic rhinitis (hay fever) caused by an allergen challenge.
- Trial name
- NCT00247520
- Testing
- topical nasal rEV131
- Where
- 2 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Evolutec Group
Seasonal Allergic Rhinitis (SAR)
A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure
This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.
- Trial name
- ALDP001 (NCT07219849)
- Testing
- ALDP001 Nasal Spray
- Where
- Canada
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Alixer Nexgen Therapeutics Limited
Fall, Age Problem
A Specific Dance Intervention in Older Adults in Hong Kong
This study is a fully-powered randomised controlled trial and an essential follow-up study of our pilot work. The 21-style specific dance intervention to improve the balance and reduce the risks of falls (SDIIBRF) was suggested…
- Trial name
- NCT06563661
- Testing
- The 21-style specific dance exercises
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
Influenza (Healthy Volunteers)
Evaluating Modes of Influenza Transmission 2b Baseline SAR
This is a research study to investigate how influenza transmits from person-to-person. Participation as a healthy "Recipient" in this study involves: Home semi-quarantine lasting about 14 days during which the participants must…
- Trial name
- EMIT-2b-1 (NCT07342556)
- Testing
- Exposure to Donors with naturally acquired influenza virus infection
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Maryland, College Park
Hospital Infection, Standardized Antibiotic Prescribing Ratio (SAR)
InPART RX - Epicenters
InPART Rx is a collaborative research study to measure the impact of a planned quality improvement initiative to reduce unnecessary antibiotic prescribing by the Hospital Medicine Service through a process of receiving…
- Trial name
- InPART RX (NCT07368660)
- Testing
- Messaging Hospitalists, Usual Care
- Where
- 4 sites in United States
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Emory University